Product NewsOXFORD BIOMEDICA RECEIVES NOTICE OF ALLOWANCE FOR KEY US PATENT COVERING PARKINSON’S DISEASE PRODUCT, PROSAVIN®
Product NewsOxford Biomedica reports new encouraging phase II results with TroVax® and progress in the development plan
Product NewsOxford Biomedica secures agreement with FDA on special protocol assessment for phase III trial of TroVax in renal cancer
Product NewsOxford Biomedica reports encouraging preclinical data with Retinostat® in Retinopathy and demonstrates the potential of Lentivector® in other ocular diseases
